Evotec SE

EVT

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    4,766

Stocks News & Analysis

stocks

Continuing problems at the ASX

Interim report by financial regulator is a hit to sentiment.
stocks

Top investing lessons from 2025

13 lessons from Morningstar’s James Gruber.
stocks

Chart of the Week: Aussie dividend yields are less attractive than alternatives

The latest insights from our equity research team.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,845.602.500.03%
CAC 408,086.0520.11-0.25%
DAX 4023,960.59116.28-0.48%
Dow JONES (US)47,885.97228.29-0.47%
FTSE 1009,774.3289.530.92%
HKSE25,468.78233.370.92%
NASDAQ22,693.32418.14-1.81%
Nikkei 22549,134.63377.65-0.76%
NZX 50 Index13,265.4430.47-0.23%
S&P 5006,721.4378.83-1.16%
S&P/ASX 2008,562.506.000.07%
SSE Composite Index3,870.2845.471.19%

Market Movers